Fludarabine and Pharmacokinetic-Targeted Busulfan before Allografting for Adults with Acute Lymphoid Leukemia

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 10, 2011, Pages 1505-1511

  Santarone, Stella ^a   Pidala, Joseph ^b   Di Nicola, Marta ^a   Field, Teresa ^b   Alsina, Melissa ^b   Ayala, Ernesto ^b   Janssen, William ^b   Kharfan Dabaja, Mohamed A ^b   Ochoa, Leonel ^b   Perez, Lia ^b   Perkins, Janelle ^b   Raychaudhuri, Jyoti ^b   Fernandez, Hugo ^b   Anasetti, Claudio ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

ALL; Busulfan; Fludarabine; HCT

Indexed keywords

BUSULFAN; FLUDARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS;

ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER SURVIVAL; CANCER TRANSPLANTATION; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA RELAPSE; MALE; MORTALITY; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; T CELL DEPLETION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDIES; SURVIVAL RATE; TACROLIMUS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 80052967904     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.02.011     Document Type: Article

References (36)

1. Rowe J.M., Buck G., Burnett A.K., et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005, 106:3760-3767.
2. Ram R, Gafter-Gvili A, Vidal L, et al. Management of adult patients with acute lymphoblastic leukemia in first complete remission: systematic review and meta-analysis. Cancer. 116:3447-3457.
3. Goldstone A.H., Richards S.M., Lazarus H.M., et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008, 111:1827-1833.
4. Mohty M., Labopin M., Volin L., et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood 2010, 116:4439-4443.
5. Kahl C., Storer B.E., Sandmaier B.M., et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2007, 110:2744-2748.
6. Zwaan C.M., Kaspers G.J., Pieters R., et al. Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia. Blood 2000, 96:2879-2886.
7. Andersson B.S., Thall P.F., Madden T., et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002, 8:477-485.
8. Bornhauser M., Storer B., Slattery J.T., et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 2003, 102:820-826.
9. de Lima M., Couriel D., Thall P.F., et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004, 104:857-864.
10. Russell J.A., Tran H.T., Quinlan D., et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002, 8:468-476.
11. Bunin N., Aplenc R., Kamani N., Shaw K., Cnaan A., Simms S. Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study. Bone Marrow Transplant 2003, 32:543-548.
12. Geddes M., Kangarloo S.B., Naveed F., et al. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant 2008, 14:220-228.
13. Hassan M., Ljungman P., Bolme P., et al. Busulfan bioavailability. Blood 1994, 84:2144-2150.
14. McCune J.S., Gooley T., Gibbs J.P., et al. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2002, 30:167-173.
15. Slattery J.T., Clift R.A., Buckner C.D., et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997, 89:3055-3060.
16. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
17. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
18. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988, 16:1141-1154.
19. Perkins J.P., Field T., Kim J., et al. Maximally tolerated busulfan area under the concentration-time curve (AUC) in combination with fludarabine as conditioning prior to allogeneic hematopoietic cell transplantation. Am Soc Hematol Annu Meet 2010.
20. Yanada M., Matsuo K., Suzuki T., Naoe T. Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis. Cancer 2006, 106:2657-2663.
21. Marks D.I., Forman S.J., Blume K.G., et al. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. Biol Blood Marrow Transplant 2006, 12:438-453.
22. Socie G., Clift R.A., Blaise D., et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood 2001, 98:3569-3574.
23. Davies S.M., Ramsay N.K., Klein J.P., et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol 2000, 18:340-347.
24. Granados E., de La Camara R., Madero L., et al. Hematopoietic cell transplantation in acute lymphoblastic leukemia: better long term event-free survival with conditioning regimens containing total body irradiation. Haematologica 2000, 85:1060-1067.
25. Yanada M., Naoe T., Iida H., et al. Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease. Bone Marrow Transplant 2005, 36:867-872.
26. Ringden O., Labopin M., Tura S., et al. A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 1996, 93:637-645.
27. Ghandi P., Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 2002, 41:93-103.
28. Madden T., de Lima M., Thapar N., et al. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant 2007, 13:56-64.
29. Russell J.A., Savoie M.L., Balogh A., et al. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin. Biol Blood Marrow Transplant 2007, 13:814-821.
30. Kiehl M.G., Kraut L., Schwerdtfeger R., et al. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol 2004, 22:2816-2825.
31. Bachanova V., Verneris M.R., DeFor T., Brunstein C.G., Weisdorf D.J. Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood 2009, 113:2902-2905.
32. Cho B.S., Lee S., Kim Y.J., et al. Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study. Leukemia 2009, 23:1763-1770.
33. Mohty M., Labopin M., Tabrizzi R., et al. Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Haematologica 2008, 93:303-306.
34. Stein A.S., Palmer J.M., O'Donnell M.R., et al. Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2009, 15:1407-1414.
35. Carpenter P.A., Snyder D.S., Flowers M.E., et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007, 109:2791-2793.
36. Lee S., Kim Y.J., Min C.K., et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2005, 105:3449-3457.